Ablynx
Ablynx developed NANOBODY® technology, a platform for designing tiny, modular antibodies used in therapeutics, and was acquired by Sanofi.
Ablynx's NANOBODY® technology platform uses tiny, modular antibodies to unlock new possibilities in drug design. The company was acquired by Sanofi, which now operates the technology platform as part of its drug development capabilities.